DOCSLIB.ORG

2018 Annual Report 2018 Our Year of Big Thinking, Collaboration and Discovery

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2018 Annual Report 2018 Our Year of Big Thinking, Collaboration and Discovery 2018 Annual Report 2018 Our year of big thinking, collaboration and discovery. Our vision Our values We see a future where everyone lives a longer, Excellence healthier life. Innovation Our mission Collaboration We will harness all the information encoded in Community the genome to make pioneering discoveries that Integrity predict, treat and prevent diseases that have the deepest impact on society. Respect 2018 Garvan Annual Report Our values Who we are, what we do Aspirations Excellence Garvan is leading the nation in using genomic analysis • To become the most advanced institute in the to accelerate discovery and enable personalised, region in the adoption, application and integration Innovation precision medicine. of next-generation genomic and computational approaches and technologies in investigative and Collaboration Our researchers pioneer studies into some of the most translational research. difficult to solve and widespread diseases affecting the Community community today. Garvan is focused on understanding • To advance knowledge in our key areas of critical the molecular and cellular processes in health and mass that will lead to better understanding, reduced Integrity disease, putting people and patients at the centre of incidence and improved treatments for cancer, leading-edge local and global research expertise and immune deficiency, inflammatory and autoimmune Respect networks as the basis for developing future preventions diseases including diabetes, osteoporosis, and and treatments. diseases of ageing affecting the brain and other organs. For 56 years, Garvan scientists have been achieving significant breakthroughs in the understanding and • To attract, develop and support exceptionally talented treatment of diseases. researchers with leading-edge programs addressing key conceptual and practical questions in human biology, and the translation of new knowledge and technologies into clinical applications. • To embrace and uphold a culture of collegiality, collaboration, inclusivity, consideration, safety, transparency, and the highest ethical standards. • To engage stakeholders and the community through our achievements and research vision so that we attract the significant government and donor support needed to empower our transformative agenda. garvan.org.au 11 The organisation As at 31 December 2018 Garvan Institute of Medical Research Board of Directors Executive Chair Dr John Schubert AO Executive Director Prof Chris Goodnow FAA FRS Chief Operating Officer Kate Gunn Chief Scientific Officer Prof Marie Dziadek Garvan Research Foundation Board of Directors Executive Chair Russell Scrimshaw Director Mara-Jean Tilley Deputy Director Brad Timms Research Divisions Bone Biology Cancer Diabetes and Metabolism Genomics and Epigenetics Head Head Head Head Prof Peter Croucher Prof David Thomas Prof Mark Febbraio Prof Susan Clark FAA Faculty Faculty Faculty Faculty A/Prof Paul Baldock Dr Christine Chaffer Prof Trevor Biden Dr Ozren Bogdanovic Prof Jacqueline Center A/Prof Elgene Lim Prof Lesley Campbell AM A/Prof Marcel Dinger Prof John Eisman AO Prof Chris Ormandy Prof Don Chisholm AO Prof Vanessa Hayes Prof Tuan Nguyen Dr Marina Pajic Prof Jerry Greenfield A/Prof Tim Mercer Prof Mike Rogers A/Prof Joseph Powell Prof Ted Kraegen Prof Seán O’Donoghue A/Prof Alex Swarbrick A/Prof Ross Laybutt Prof John Shine AO FAA A/Prof Paul Timpson Prof Katherine Samaras Prof Neil Watkins A/Prof Carsten Schmitz- Peiffer The Kinghorn Cancer Centre Director Prof David Thomas Immunology Neuroscience Kinghorn Centre for Garvan-Weizmann Centre Clinical Genomics for Cellular Genomics Head Prof Stuart Tangye Head A/Prof Antony Cooper Clinical Head Head A/Prof Joseph Powell Faculty Faculty Mary-Anne Young Prof Antony Basten AO FAA FTSE Prof Herbert Herzog Prof Robert Brink Prof John Mattick AO FAA FTSE Scientific Head Prof Daniel Christ Prof David Ryugo A/Prof Sarah Kummerfeld Dr Tatyana Chtanova Dr Robert Weatheritt Dr Elissa Deenick Prof Chris Goodnow FAA FRS A/Prof Shane Grey A/Prof Cecile King A/Prof Tri Phan Prof Jonathan Sprent FAA FRS Genome.One Chief Executive Officer A/Prof Marcel Dinger Development and Support Chief Operating Officer Kate Gunn Chief Scientific Officer Prof Marie Dziadek Australian BioResources: Dr Jenny Kingham Grants Administration: Sonja Bates & Grainne Mullen Business Development & Innovation: David Barda Human Research Governance: Therese Yim Finance & Accounting: Samantha Malone Animal Ethics: Dr Rayson Tan Human Resources: Simon Hamilton Animal Welfare Officer: Dr Vivian Song Internal Audit & Business Improvement: Carolyn Loughnan Student Programs: Dr Tracy Anderson Information Technology: Esteve Mayolas, Jackson Chan Legal Counsel: Christina Hardy Building Services: Lynn Croft Engineering Services: Ryan Kolster Facilities: Julie Miller Scientific Support Services: Rebecca Brown WHS and Compliance: Lisa Moncur 2 2018 Garvan Annual Report Contents 4 Garvan Institute Chairman 33 Division Report: and Executive Director’s Neuroscience Report 35 Microsoft cloud computing 5 Garvan Research grant to support Garvan’s Foundation Chairman and genomic research Director’s Report 36 Centre Report: 6 The year at a glance Kinghorn Centre for Clinical Genomics 7 Garvan at a glance 38 Centre Report: 8 Collaborations Garvan-Weizmann Centre 9 Publications for Cellular Genomics 10 Awards and achievements 40 Garvan Institute of Medical Research Board of Directors 13 Division Report: Bone Biology 43 Garvan Research Foundation Board of 15 Ellie’s story: from intensive Directors care to the playground 46 PhD completions 16 Division Report: Cancer 47 Post-Doctoral 19 Taking genomic cancer Development Committee medicine national 48 Franklin Women’s 21 Division Report: Academic Partners Diabetes and Metabolism 49 In Memoriam 23 A pioneering partnership 50 Leaders in Science and 25 Division Report: Society seminars Genomics and Epigenetics 51 A shared vision for a 27 A national genomics healthier future mission for Australia 52 Partners for the Future 28 Division Report: Immunology 54 Garvan community 31 UNSW Cellular Genomics 60 Scientific publications Futures Institute launches 78 Peer reviewed funding 84 Financial highlights We would like to acknowledge the Gadigal people of the Eora Nation, the traditional owners and custodians of the land on which the Garvan Institute of Medical Research is located. We pay respects to the Elders, past, present and future, and recognise the continuing connection and contribution to this land. A digital version of this report is available at garvan.org.au/ 2018-annualreport. garvan.org.au 3 Garvan Institute of Medical Research Report In 2018 the Garvan Institute of Medical the application of single-cell genomics and Research embraced change under new bioinformatics in a broader genomics and leadership, and celebrated numerous precision medicine framework. scientific achievements. Our talented researchers continued their pursuit of With thanks to your ongoing support, the discoveries to better predict, prevent Institute is in great shape. Our Garvan family and treat a wide range of diseases with raised more than $41 million in philanthropic the aim of giving everyone a shot at funding to catalyse and accelerate research a longer, healthier life. discoveries, and our scientists attracted $24 million in critical competitive peer- Garvan continues to be a world leader in reviewed funding. Our research discoveries genomics-led research and translation. were published in prestigious scientific Genomics – the study of all the information in journals – an important measurement of our DNA – is and will continue to revolutionise Garvan’s success and crucial to ensuring Dr John Schubert AO health care. Our strategic research centres our findings are disseminated globally Chairman – The Kinghorn Cancer Centre, the Kinghorn within the medical community. Centre for Clinical Genomics and the Garvan- Weizmann Centre for Cellular Genomics – Throughout 2018, Garvan’s work, at the ensure Garvan scientists, and the research intersection between research and clinical community, are able to pioneer human- care has resulted in life-changing treatments centred research which will be translated for people, such as Ellie (page 15) through the into clinical practice for the benefit of all. Zero Childhood Cancer Program. 2018 also saw us formalise a partnership The executive leadership of the Institute between Genome.One, our wholly owned continues to excel; we are appreciative of subsidiary providing clinically accredited the passion and skill of Professor Marie whole genome sequencing, and pathology Dziadek as Chief Scientific Officer, Kate Gunn company Australian Clinical Labs. This new (following Philip Knox) as Chief Operating partnership is translating Garvan’s genome Officer, Mara-Jean Tilley (following Andrew sequencing and analysis capabilities into a Giles) as Director of the Garvan Research critical diagnostic service, serving families Foundation, and our research leaders: and doctors across Australia. Drawing upon Professor Susan Clark, Associate Professor Professor Chris Goodnow FAA FRS the very best of Garvan’s cutting-edge Antony Cooper, Professor Peter Croucher, Executive Director research, this service has already changed Professor Mark Febbraio, Professor Stuart young lives and transformed the care of many Tangye and Professor David Thomas. Australians. It is now set to do even more. Of course Garvan is nothing without its people, and we warmly acknowledge the Following the launch of the Australian Federal
Load more

Recommended publications
  • The John Curtin School of Medical Research Annual Review 2012
    THE JOHN CURTIN SCHOOL OF MEDICAL RESEARCH ANNUAL REVIEW 2012 ANU College of Medicine, Biology & Environment CONTENTS Annual Review 2012 From the Director 3 The John Curtin School of Medical Organisation Chart 4 Research Committees 5 COMMUNITY 7 Official Opening of Stage 3 8 Launch of The John Curtin Medical Research Foundation 9 Professor Gordon Ada 10 Open Day 11 Community Activities 12 RESEARCH IN REVIEW 2012 15 Eccles Institute of Neuroscience 16 Department of Genome Biology 29 Department of Immunology 36 Department of Pathogens and Immunity 45 Department of Molecular Bioscience 47 Department of Translational Medicine 56 Australian Phenomics Facility 60 Biomolecular Resource Facility/Genome Discovery Unit 61 STAFF AND STUDENT ACHIEVEMENTS 63 VISITORS AND COLLABORATIONS 69 STAFF AND STUDENTS 85 Department of Genome Biology 86 Department of Immunology 87 Eccles Institute of Neuroscience 88 Department of Pathogens and Immunity 90 Department of Molecular Bioscience 90 Department of Translational Medicine 92 APF and Animal Services 92 School Services 94 School Administration 95 Students 96 PUBLICATIONS, PRESENTATIONS AND COMMUNITY OUTREACH 99 SUPPORT 129 Grants 130 Financial Overview 134 Donors 135 Sponsors 136 Annual Review 2012 1 2 The John Curtin School of Medical Research FROM THE DIRECTOR Zinkernagel. He will be sadly missed by his many friends and colleagues at the School, who have established the annual Gordon Ada New Investigator Award in his memory. In 2012, we finally completed the long and very necessary redevelopment project that resulted in the new John Curtin School of Medical Research building on the ANU campus. All our staff and students are once again under one roof, carrying out their research in state of the art laboratories and facilities.
    [Show full text]
  • Understanding Genomics
    Predict Diagnose Treat Understanding genomics A comprehensive guide brought to you by Garvan. Contents What is genomics? 4 A short history of DNA 5 Genomics information for a lifetime 7 Conversations about genomics 11 How does genome sequencing work? 12 Can I have my genome sequenced? 13 Genomics research at Garvan 14 Garvan’s genomics research programs 18 Genomics research centres 20 Useful terms 22 Predict Diagnose Treat 2 3 Professor Chris Goodnow FAA FRS Executive Director, Garvan Institute of Medical Research The Bill and Patricia Ritchie Foundation Chair Dear Friend, I’m Professor Chris Goodnow, Executive Director of the Garvan Institute of Medical Research in Sydney. I wanted to introduce myself and thank you for your interest in understanding genomics. Genomics is the study of genes and other information encoded in an individual’s genome—the complete set of instructions in their DNA. Each person has different DNA, unique just to you. Every disease has a genetic component. Through genomics research, we can further understand what our genetic information – and our gene or genetic variations – mean for our health. Garvan scientists use genomics research to understand more about disease and determine how to best diagnose, treat and prevent it. I hope you find this brochure informative and useful and consider joining our family, pioneering the future of medical research. Yours sincerely, Chris We see a future where an individual’s DNA is used to better predict, diagnose and treat disease. It’s within reach. 2 3 What is genomics? Genomics is the study of your genome – all the information encoded in your DNA.
    [Show full text]
  • Annual Report (March 2010-February 2011)
    EMBL Australia Annual Report [March 2010 – February 2011] 2 EMBL AUSTRALIA ANNUAL REPORT 2009–10 Contents Chairman’s report 2 Scientific Head’s report 3 About EMBL Australia 4 The European Molecular Biology Laboratory 4 2010 Highlights 5 2011 Outlook 6 Key activities 7 Launch by Minister Carr 7 Appointment of Scientific Head 8 EBI Mirror Facility and the National Bioinformatics Network 8 EBI Mirror at The University of Queensland 8 EMBL Australia Bioinformatics Network 9 International PhD Program 9 Partner Laboratory Network 9 Appointment of Edwina McGlinn 10 Appointment of Nicolas Platcha 11 Faculty Development Program 11 Sponsorship of BioInfoSummer 11 Governance 12 EMBL Australia participant expansion 12 Council 12 Appointment of new members 12 Council Members 12 Meetings 12 Planning and Finance Committee 13 Members 13 Meetings 13 Bioinformatics Committee 13 Members 13 Meetings 13 Staff 14 Australian visitors to EMBL 2010 15 Visitors to EMBL Australia 15 Financial report 16 Documents and Media releases 18 Funding & Stakeholders 20 Participants 20 Funding and in-kind support 20 Contact details inside back cover 1 Chairman’s report 2010 was a seminal year in the EMBL Australia initiative. Our official launch by Minister Carr in March coincided with the announcement of several key developments. These developments included the appointments of our Scientific Head and first Partner Laboratory Group Leaders, along with the announcement of a second node and associated national network for bioinformaticians. EMBL Australia’s participation is set to expand, with invitations accepted by the remaining Go8 universities to join EMBL Australia. This will extend direct involvement to a wider group of research institutions and expand the potential reach of EMBL Australia programs.
    [Show full text]
  • June 06.Indd
    NEWSLETTER Australasian Society for Immunology Incorporated PP 341403100035 ISSN 1442-8725 June 2006 Overview of the JCSMR Immunogenomics Laboratory 2006 Gerard Hoyne Overview they were able to reveal that the autoimmune but Dr Horikawa, a postodoctoral fellow in The Immunogenomics Laboratory at the regulator gene AIRE, which is expressed by the lab, has made the remarkable fi nding that John Curtin School of Medical Research in a subset of thymic epithelial cells, plays a the exact opposite is the case. The memory Canberra comprises four research groups critical role in establishing T cell tolerance B cell receptor is less active at inducing a working in concert to develop an integrated to self antigens in the thymus. In addition, subset of genes, and in this case less signal understanding of how our immune system is Adrian also identifi ed that defective signals means more antibody formation. controlled at the cellular and molecular level to cell death genes account for the inherited by circuits that are specifi ed in our genome resistance of T lymphocytes to clonal deletion Carola Vinuesa heads the Humoral sequence. Each of the groups focuses on in the thymus of NOD mice. Upon infection memory and Autoimmunity Group. a different element of a fundamental set with a virus or bacteria, B lymphocytes with Her group is investigating the cellular and of immune system decisions made at the the right antigen receptors to neutralize molecular events that regulate production level of individual immune system cells: infection are stimulated to switch the isotype and selection versus elimination of memory either to fi ght or to disarm.
    [Show full text]
  • THE JOHN CURTIN SCHOOL of MEDICAL RESEARCH Annual Review 2013
    THE JOHN CURTIN SCHOOL OF MEDICAL RESEARCH Annual Review 2013 ANU College of Medicine, Biology & Environment CONTENTS Annual Review 2013 The John Curtin School of Medical Research From the Director 3 Staff and student lists 87 Department of Genome Biology 88 Organisation Chart 4 Department of Immunology 90 Committees 5 Eccles Institute of Neuroscience 92 Department of Molecular Bioscience 94 Community 7 Department of Translational Medicine 96 Department of Pathogens and Immunity 96 Centenary of Canberra 2013 Australian Phenomics Facility 97 14th Frank and Bobbie Fenner Conference 8 School Administration 98 The John Curtin Medical Research Foundation Dinner 9 School Services 98 David Curtis Reading Room 10 The ACRF Biomolecular Resource Facility Open Day 2013 11 and Genome Discovery Unit 99 Community Activities 12 Students 100 Research in Review 2013 15 Publications, presentations and Eccles Institute of Neuroscience 16 community outreach 103 Department of Genome Biology 30 Publications 104 Department of Immunology 38 Staff Presentations 110 Department of Pathogens and Immunity 48 Student Presentations 117 Department of Molecular Bioscience 52 Community Outreach 121 Department of Translational Medicine 58 Australian Phenomics Facility 60 Support to JCSMR 131 The Imaging and Cytometry Facility 62 Grants 132 The ACRF Biomolecular Resource Facility Financial Overview 136 and Genome Discovery Unit 63 Donors 137 Staff and student achievements 65 Sponsors 138 Graduates 66 Prizes and Awards 67 Visitors and collaborations 71 Visitors 72 Collaborations 74 Annual Review 2013 1 2 The John Curtin School of Medical Research FROM THE DIRECTOR Following the opening of Stage 3 of our new building in 2012, JCSMR staff and students have enjoyed the opportunities provided by the new spaces, including the laboratories, and meeting rooms such as the Science Forum.
    [Show full text]
  • 2019 Annual Report
    Annual Report 2019 Garvan Institute of Medical Research Annual Report 2019 2019 Strength through collaboration Our vision Our values We see a future where everyone lives a longer, healthier life. Excellence Our mission Innovation We will harness all the information encoded in the genome Collaboration to better diagnose, predict, treat and prevent diseases that have the deepest impact on society. Community Integrity Respect Who we are, what we do The Garvan Institute of Medical Research brings together world-leading clinicians and basic and translational researchers. We are patient focused. Our researchers break down barriers between traditional scientific disciplines to find solutions to disease. Founded in 1963, Garvan’s researchers have made significant advances in genome, epigenome, protein and cell analysis technology. We have revealed causes and developed treatments for diseases including diabetes, osteoporosis, cancer, immune deficiency and autoimmunity. Today, Garvan’s mission builds on those advances, harnessing all the information encoded in our genome, from DNA to complex organ systems, to better diagnose, treat, predict and prevent disease. Garvan’s research has global impact. World-leading people pioneer discoveries across four intersecting research themes. We lead the field in medical genomics, epigenetics, and cellular genomics; cancer; diseases of immunity and inflammation; and diseases of ageing affecting bone, brain and metabolism. Our goal is to translate discovery into meaningful health benefits for those living with disease and their family. Patients, clinical trial cohorts and population cohorts are at the centre of Garvan’s research. We are focused on addressing the unmet needs of those living with disease – where better understanding, new treatments and more effective diagnosis can have the biggest impact.
    [Show full text]
  • SMEC 2019 Sustainability Report
    Sustainability Report 2019 CONTENTS 04 Message from the CEO 06 Our Company and the Surbana Jurong Group 07 Our Global Footprint 08 2019 Highlights 12 Our Organisation 12 - Our Board 13 - Our Executive Committee 14 - Stakeholder engagement 16 - Core values 18 - Awards and rankings 20 - Corporate governance 24 - Financial performance 26 People 26 - Employee demographics 26 - Remuneration 28 - Employee benefits 28 - Health and wellbeing 29 - Gender diversity 30 - Career development 34 Community 34 - Human Rights 36 - Community Development 38 Sustainability and Environment 44 Appendix A: Scope of the report 46 Appendix B: Associated and controlled entities 48 Appendix C: Company memberships 50 Appendix D: EIA scale 52 Appendix E: GRI Index Yarranlea Solar Farm • Australia Message from the CEO At SMEC, we provide sustainability services for a range of infrastructure projects to push environmental, social and economic project outcomes beyond ‘business as usual’ The work done in 2018 to revise and enhance SMEC Australia’s Graduate Development Program was also recognised by the industry, with the program winning a Gold award for Best Learning & Development Project (Induction/ Onboarding) and a Silver award for Best Learning Model (Blended Learning) at the 2019 LearnX awards. As always, we are committed to a safety-first environment, and to investing in the wellbeing of our people. In line with the strategy endorsed in 2018, SMEC’s Mental Health First Aid Network was established in 2019. There are now specially trained Mental Health First Aiders (MHFAs) in each Australian state or territory, and in New Zealand. I am proud that the SMEC Foundation was named an ABA100 Winner for Community Contribution in the Australian Business Awards 2019.
    [Show full text]
  • 2017 Annual Report GARVAN INSTITUTE of MEDICAL RESEARCH MISSION and VISION
    BREAKTHROUGH MEDICAL RESEARCH 2017 Annual Report GARVAN INSTITUTE OF MEDICAL RESEARCH MISSION AND VISION To make significant contributions to medical research that will change the directions of science and medicine and have major impacts on human Respect Passion health. Garvan’s ultimate goal is prevention and treatment of major diseases. Collaboration Values Excellence Innovation Integrity Who we are, Aspirations • To attract, develop and support exceptionally talented what we do • To become the most researchers with leading‑edge advanced institute in the programs addressing key Garvan is leading the nation region in the adoption, conceptual and practical in using genomic analysis to application and integration of questions in human biology, accelerate discovery and enable next‑generation genomic and and the translation of new personalised, precision medicine. computational approaches and knowledge and technologies technologies in investigative into clinical applications. Our researchers pioneer and translational research. studies into some of the most • To embrace and uphold a culture widespread diseases affecting • To advance knowledge in our of collegiality, collaboration, the community today. Garvan is key areas of focus that will inclusivity, consideration, focused on understanding the lead to better understanding, safety, transparency, and role of molecular and cellular reduced incidence and high ethical standards. processes in health and disease improved treatments for cancer, as the basis for developing future osteoporosis, diabetes, obesity, • To engage stakeholders preventions and treatments. and immunological, skeletal and and the community with our neurological diseases, and achievements and research For 55 years, Garvan to influence health policy. vision so that we attract the scientists have been achieving significant government and significant breakthroughs donor support needed in the understanding and to empower our treatment of diseases.
    [Show full text]
  • Breakthrough Magazine June E Corkery Angele Labossiere Eric Swarbrick Please Visit Garvan.Org.Au/Previous-Seminars
    August 2018 | Issue 39 breakthrough Trust your gut How your bacteria could save you from type 2 diabetes Meet Professor Chris Goodnow, Garvan’s new Executive Director Living an extraordinary life with rare cancer Welcome NEW RESEARCH from our It’s DNA, but not as we know it Executive In a world first, our researchers Associate Professor Daniel Christ, Associate Professor Marcel Dinger and Director Dr Mahdi Zeraati found a new DNA structure – a twisted ‘knot’ they call the i-motif – inside cells. The iconic ‘double helix’ shape of DNA has captured the public imagination since 1953; however, it’s now known that DNA can exist Dear Garvan family, in a few other shapes – in a test tube, at least. Until now, the i-motif had never before been directly seen inside I’m so pleased to be able to introduce your August issue of living cells. In fact, scientists had debated whether i-motif Breakthrough and to have this opportunity to thank you for ‘knots’ would exist at all inside living things – a mystery your support. Many of you know me from my three years as that is now solved. Garvan researchers suspect i-motif Deputy Director here at Garvan. I’m honoured to have been DNA plays an important role in switching genes on or off. appointed as the Institute’s fourth Executive Director and build on the legacy of the Institute’s pre-eminent leaders. See the i-motif DNA at garvan.org.au/new-dna. I’d like to briefly share with you my vision for the future of Garvan, in which we continue our progress towards precision medicine based on each person’s DNA.
    [Show full text]
  • Garvan Institute's Guide to Positive Ageing
    Positive ageing A comprehensive guide brought to you by Garvan. PB 1 Contents Introduction 1 What is healthy ageing? 2 What happens to your body as it ages 4 Diseases of ageing 12 Healthy ageing – what you can do 14 Garvan & diseases of ageing 16 Medical Genome Reference Bank 24 We see a future where everyone lives longer, healthier lives. 1 Professor Chris Goodnow FAA FRS Executive Director, Garvan Institute of Medical Research The Bill and Patricia Ritchie Foundation Chair Dear Friend, I’m Professor Chris Goodnow, Executive Director of the Garvan Institute of Medical Research, one of Australia’s premier research facilities. I wanted to introduce myself and thank you for requesting our brochure on positive ageing. As precision medicine and advances in healthcare enable people to live longer than ever before, the ability to live not only long, but healthy lives is becoming increasingly critical. We know that ageing healthily relies on a complex mix of genetic, environmental and social factors. However, there are actions that can be taken now to help ensure that older adults maintain their physical and emotional health, whatever their age or circumstances. We are focused on addressing the unmet needs of those living with disease – where better understanding, new treatments and more effective diagnosis can have the biggest impact in order to create a future where people can live longer, healthier lives. Yours sincerely, Chris We see a future where an individual’s DNA is used to better predict, diagnose and treat disease. It’s within reach. 1 What is healthy ageing? With age comes the increased risk of disease or infirmity.
    [Show full text]
  • SMEC Sustainability Report 2018 SMEC Sustainability Report 2018 5 Our Company
    Sustainability Report 2018 Contents Foreword 4 Our company 6 Global footprint 7 2018 Sustainability highlights 8 Sustainability objectives 10 Our organisation 12 Our Board 12 Our Executive Committee 14 Stakeholder engagement 16 Core values 18 Corporate governance 20 Awards and rankings 24 Financial performance 26 People 28 Employee demographics 28 Remuneration 29 Employee benefits 30 Health and wellbeing 30 Gender diversity 31 Career development 32 Community 36 Human rights 36 Community development 38 Sustainability and Environment 40 Appendix A: Scope of the report 46 Appendix B: Associated and controlled entities 48 Appendix C: Company memberships 50 Appendix D: EIA scale 52 Appendix E: GRI Index 54 Canberra Metro Consortium ACT Foreword Welcome to our ninth annual Sustainability Report which outlines our progress towards our sustainability objectives and the environmental outcomes we influence through our projects and services. Sustainability is top of mind and a topic of much We bring this approach to life by taking We also implemented several initiatives Our combination of engineering and a long-term view in everything we do to ensure a more diverse, satisfying and environmental skills enables us to "Sustainability at SMEC is a discussion for many organisations. For SMEC, and ensuring that as an organisation we rewarding work environment for our effectively help our clients achieve operate sustainably and make a positive people. These include increased paid sustainable outcomes. We have journey. As we gain a greater sustainability is about continuity and resilience. impact on our communities. We are parental leave, global leadership training successfully delivered over 31,000 MW passionate about collaborating with our programs, the launch of our Safety Culture of hydropower over the last 15 years, understanding of issues, clients and partners to build effective Action Plan and the development of and our specialists have taken a leading or identify opportunities to and sustainable solutions.
    [Show full text]
  • Mutations, Tolerance Checkpoints, Autoimmunity and Lymphoid Cancer
    Mutations, tolerance checkpoints, autoimmunity and lymphoid cancer PROFESSOR CHRISTOPHER C GOODNOW FAA FRS Executive Director, Garvan Institute of Medical Research ABSTRACT Distinguishing self from microbe is a fundamental problem for adaptive and innate immune receptors, balancing between the need for specificity and polyreactivity. Self-reactive antibodies are displayed as surface receptors on many B lymphocytes, and continuously signal responses within the B cell upon binding self antigens. A series of checkpoints and feedback mechanisms normally prevent these signals from activating relentless B cell proliferation and the potential for autoimmunity or lymphoma/leukemia. Here I will describe recent experiments analysinghow cells bypass these checkpoints by acquiring somatic mutations in the immunoglobulin V-regions and in lymphoma driver genes. 31 Thursday 1 August, 2019 ABOUT THE PRESENTER 1:00 - 2:00pm Professor Chris Goodnow FAA FRS is Executive Director of the Garvan Institute of Medical Research, holds The Bill and Patricia Ritchie Foundation H1 Lecture Theatre, Chair as Head of the Immunogenomics Laboratory at Garvan, and is Professor and Director of the Cellular Genomics Futures Institute at UNSW 20 Chancellors Walk Sydney. Chris trained in veterinary medicine and surgery, immunochemistry, Clayton campus and immunology at the University of Sydney and in DNA technology at Stanford University. Chris is internationally recognised for discovering and establishing the concept of sequential checkpoints for the immune system to tolerate “self” while fighting off “foreign” infections, laying the scientific foundation for the recent success of checkpoint inhibitor drugs to activate immune destruction of “self” cancer cells. He pioneered the use of genome sequencing to reveal how the body’s phenotype results from its’ genotype – “phenomics”.
    [Show full text]